연구성과 홍보

Gut Microbes. 2024 Jan-Dec;16(1):2412376.

Title : Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products

Authers : Do-Yeon Kim1, So-Yeon Lee1, Jae-Yun Lee1, Tae Woong Whon2, June-Young Lee1,3, Che Ok Jeon4, Jin-Woo Bae1,3

Affiliations :

1Department of Life and Nanopharmaceutical Sciences and Department of Biology, Kyung Hee University, Seoul, Korea.

2Microbiology and Functionality Research Group, World Institute of Kimchi, Gwangju, Korea.

3Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul, Korea.

4Department of Life Science, Chung-Ang University, Seoul, Korea.

DOI : 10.1080/19490976.2024.2412376.

Abstract :

The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.

Keywords : CDI; FMT; Gut microbiome; IBD; LBP; cancer; dysbiosis; metabolic disorders; neurological disorders.